Gender differences in prevalence of hepatitis C virus infection in Egypt: a systematic review and meta-analysis

Abdel-Gawad, Muhammad; Nour, Mohamed O.; El-Raey, Fathiya; Nagdy, Hanaa; Almansoury, Yahya; El-Kassas, Mohamed

doi:10.1038/s41598-023-29262-z

Cited by 7 publications

(3 citation statements)

References 46 publications

(36 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the heat map plots showed that age and gender have weak correlations with other features, there is some evidence and studies show that they are important factors related to hepatitis C. A systematic review and meta-analysis was conducted by Muhammad Abdel-Gawad et al [ 24 ] to evaluate and analyze the gender differences in hepatitis C regarding the virus infection rates. They found that the HCV RNA positivity rate is significantly higher in male adults than female.…”

Section: Discussionmentioning

confidence: 99%

Performance Comparison of Machine Learning Approaches on Hepatitis C Prediction Employing Data Mining Techniques

2023

View full text Add to dashboard Cite

Hepatitis C is a liver infection caused by the hepatitis C virus (HCV). Due to the late onset of symptoms, early diagnosis is difficult in this disease. Efficient prediction can save patients before permeant liver damage. The main objective of this study is to employ various machine learning techniques to predict this disease based on common and affordable blood test data to diagnose and treat patients in the early stages. In this study, six machine learning algorithms (Support Vector Machine (SVM), K-nearest Neighbors (KNN), Logistic Regression, decision tree, extreme gradient boosting (XGBoost), artificial neural networks (ANN)) were utilized on two datasets. The performances of these techniques were compared in terms of confusion matrix, precision, recall, F1 score, accuracy, receiver operating characteristics (ROC), and the area under the curve (AUC) to identify a method that is appropriate for predicting this disease. The analysis, on NHANES and UCI datasets, revealed that SVM and XGBoost (with the highest accuracy and AUC among the test models, >80%) can be effective tools for medical professionals using routine and affordable blood test data to predict hepatitis C.

show abstract

Section: Discussionmentioning

confidence: 99%

Performance Comparison of Machine Learning Approaches on Hepatitis C Prediction Employing Data Mining Techniques

2023

View full text Add to dashboard Cite

show abstract

“…In Africa, HCV is a substantial public health problem, with prevalence rates varying greatly throughout the continent, ranging from 1 to 1.6% in some areas to more than 10% in others [33,34]. Tus, to evaluate the efectiveness of DAAs in this local setting, it is crucial to consider the experience of African countries with these treatments [18,32,[34][35][36][37].…”

Section: Discussionmentioning

confidence: 99%

“…With one of the highest HCV prevalences, Egypt doubled its eforts to achieve HCV control using several DAA regimens [32][33][34][35][36][37][38]. Many clinical trials sought to assess the efcacy and safety of the combination of sofosbuvir/daclatasvir in the country, and the fndings reported the high efectiveness and tolerance of the combination in the treatment of chronic HCV [30,31,36,38,39].…”

Section: Discussionmentioning

confidence: 99%

Efficacy of Sofosbuvir/Daclatasvir in a Single Tablet for Treating Chronic Viral Hepatitis C

Debzi,

Berkane,

Manouni

et al. 2023

Journal of Clinical Pharmacy and Therapeutics

View full text Add to dashboard Cite

Background. Published data regarding the real-life application of the combination sofosbuvir/daclatasvir in Algeria are lacking. Therefore, we conducted an observational study to assess the efficacy and safety of this regimen in Algerian patients with chronic hepatitis C. Methods. We carried out a multicentric, observational, open-label study to assess the efficacy and safety of the generic fixed-dose combination (FDC) sofosbuvir/daclatasvir in patients with chronic hepatitis C. We included 100 patients with all genotypes for 12 or 24 weeks of treatment without ribavirin. The primary outcome was the proportion of patients with a sustained virologic response (SVR) 12 weeks after treatment cessation. The secondary outcome assessed the safety and occurrence of adverse events. This study is registered with ClinicalTrials.gov identifier: NCT05138523. Results. The full analysis set included 99 patients with a mean age of 51.4 ± 14.4 years and a sex ratio of M/F = 0.86. Our patients were infected with HCV genotype 1b (n = 47), 2 (n = 17), 1a (n = 3), 2a/2c (n = 2), 3 (n = 2), and 4 (n = 1). A total of 27 patients had missing genotype data. Most patients were naive noncirrhotic (n = 70) and took 12 weeks of treatment, 19 patients had cirrhosis, of which 68.42% (n = 13) were classified as Child–Pugh A, and 5 patients were treatment-experienced. Both cirrhotic and treatment-experienced patients took 24 weeks of treatment. Efficacy analysis was conducted on 95 patients, and the results showed that 91 patients achieved SVR12 with a response rate of 95.8% (95% CI: 92–100%). Six adverse events occurred and were minor and manageable. Conclusion. Our results demonstrate the efficacy and safety of sofosbuvir/daclatasvir in single tablets in treating Algerian HCV patients without ribavirin for 12 or 24 weeks. The promising results of this study warrant further trials to assess the efficacy and safety of this combination in treating special populations.

show abstract

Anti-Hepatitis C Antibody Carriage and Risk of Liver Impairment in Rural-Cameroon: Adapting the Control of Hepatocellular Carcinoma for Resource-Limited Settings

Kamga Wouambo,

Panka Tchinda,

Kagoue Simeni

et al. 2023

Preprint

View full text Add to dashboard Cite

Background: The global Viral hepatitis elimination by 2030 is uncertain in resource-limited settings (RLS), due to high burdens and poor diagnostic coverage. This sounds more challenging for hepatitis C virus (HCV) given that antibody (HCVAb) sero-positivity still lacks wide access to HCV RNA molecular testing. This warrants context-specific strategies for appropriate management of liver impairment in RLS. We herein determine the association between anti-HCV positivity and liver impairment in an African RLS. Methods: A facility-based observational study was conducted from July-August 2021 among individuals attending the St Monique Health Center at Ottou, a rural community of Yaounde,Cameroon. Following a consecutive sampling, consenting individuals were tested for anti-HCV antibodies, hepatitis B surface antigen (HBsAg) and HIV antibodies (HIVAb) as per the national guidelines. After excluding positive cases for HBsAg and/or HIVAb, liver function tests (ALT/AST) were performed on eligible participants (HBsAg and HIVAb negative) and outcomes were compared according to HCVAb status; with p<0.05 considered statistically significant. Results: Out of 306 eligible participants (negative for HBsAg and HIVAb) enrolled, the mean age was 34.35±3.67 years. 252(82.35%) were female and 129 (42.17%) were single. The overall HCVAb sero-positivity was 15.68%(48/306), with 17.86% (45/252) among women vs. 5.55%(3/54) among men [OR (95%CI)=3.69(2.11-9.29),p=0.04]. HCVAb Carriage was greater among participants aged >50 years compared to younger ones [38.46%(15/39) versus 12.36% (33/267) respectively, OR(95%CI)=4.43(2.11-9.29), p<0.000] and in multipartnership [26.67%(12/45)vs.13.79%(36/261) monopartnership, OR (95%CI)= 2.27(1.07-4.80),p=0.03]. The liver impairment rate (abnormal ALT+AST levels) was 30.39%(93/306), with 40.19%(123/306) of abnormal ALT alone. Moreover, the burden of Liver impairment was significantly with aged>50 versus younger ones [69.23% (27/39) versus 24.72%(66/267) respectively, p<0.000). Interestingly, the burden of liver impairment (abnormal AST+ALAT) was significantly higher in HCVAb positive (62.5%, 30/48) versus HCVAb negative (24.42%, 63/258) participants, OR: 3.90 [1.96; 7.79], p=0.0001. Conclusions: In this rural health facility, HCVAb is highly endemic and the burden of liver impairment is concerning. Interestingly, HCVAb carriage is associated with abnormal liver levels of enzyme (ALT/AST), especially among the elderly populations. Hence, in the absence of nuclei acid testing, ALT/AST are relevant sentinel markers to screen HCVAb carriers who require monitoring/care for HCV-associated hepatocellular carcinoma in RLS. Keywords Hepatitis C Virus antibodies (HCVAb), ASAT/ALAT, liver impariment, hepatotoxicity, Cameroon.

show abstract

Gender differences in prevalence of hepatitis C virus infection in Egypt: a systematic review and meta-analysis

Cited by 7 publications

References 46 publications

Performance Comparison of Machine Learning Approaches on Hepatitis C Prediction Employing Data Mining Techniques

Performance Comparison of Machine Learning Approaches on Hepatitis C Prediction Employing Data Mining Techniques

Efficacy of Sofosbuvir/Daclatasvir in a Single Tablet for Treating Chronic Viral Hepatitis C

Anti-Hepatitis C Antibody Carriage and Risk of Liver Impairment in Rural-Cameroon: Adapting the Control of Hepatocellular Carcinoma for Resource-Limited Settings

Contact Info

Product

Resources

About